This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nademanee, K. Articles by Singh, B. N. Search for Related Content PubMed PubMed Citation Articles by Nademanee, K. Articles by Singh, B. N.

Circulation, Vol 72, 555-564, Copyright © 1985 by American Heart Association

ARTICLES

Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias

K Nademanee, G Feld, J Hendrickson, PN Singh and BN Singh

Sotalol is a unique beta-blocker that lengthens cardiac repolarization and effective refractory period (ERP). Its efficacy after intravenous (1.5 mg/kg) and oral (160 to 480 mg bid) administration was therefore evaluated in 37 patients with refractory recurrent ventricular tachycardia/fibrillation (VT/VF). Thirty-five patients, 33 with inducible VT/VF, underwent electrophysiologic testing. Intravenous sotalol lengthened the ERP in the atrium (+24.6%, p less than .01), atrioventricular node (+24.9%, p less than .01), and ventricle (+14.9%, p less than .01). It also significantly lengthened sinus node recovery time, corrected QT interval (QTc), and the AH interval, but not the HV interval. Sotalol prevented reinduction of VT/VF in 15 patients (45.5%). Twenty-five of the 33 patients (15 with positive results of electrophysiologic tests; 10 with negative results) were given oral sotalol. The drug was ineffective in seven (26.9%) and aggravated arrhythmia in one (3.8%). In four patients sotalol was withdrawn because of side effects; arrhythmias recurred late in two (7.7%). Eleven patients (42.3%) have continued on oral sotalol over a mean follow-up period of 9.2 +/- 8.6 months. Sotalol reduced (n = 21) total premature ventricular complex (PVC) count on the Holter electrocardiogram by 73% (p less than .01), paired PVCs by 89% (p less than .01), and beats of ventricular tachycardia by 95% (p less than .01). In 52% (n = 11), total reduction in PVCs was at least 85%, and incidence of paired and tachycardiac beats was reduced at least 90% (group A). In the remainder (n = 10), PVC suppression was not significant (group B). Group A included nine patients with nonreinducible VT/VF and two in whom it was reinducible; in group B, eight of 10 patients had reinducible VT/VF. The difference between the two groups (Fisher exact test) was significant (p less than .01). The prevention of reinduction of VT/VF by intravenous sotalol and suppression of spontaneously occurring arrhythmias by the oral drug were both predictive of long-term drug efficacy. Sotalol is a significant advance in the short- and long-term management of life- threatening ventricular tachyarrhythmias.

This article has been cited by other articles:

				R. A. Kloner A Salute to Our Founding Editor-in-Chief Bramah N. Singh, MD, DPhil, DSc, FRCP Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 154 - 156. [PDF]

				C. Mewis, V. Kuhlkamp, J. Mermi, R. F. Bosch, and L. Seipel Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1989 - 1995. [Abstract] [Full Text] [PDF]

				P. Kovoor, V. Eipper, K. Byth, M.J. Cooper, J.B. Uther, and D.L. Ross Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease Eur. Heart J., March 1, 1999; 20(5): 364 - 374. [Abstract] [PDF]

				V. Kuhlkamp, C. Mewis, J. Mermi, R. F. Bosch, and L. Seipel Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment J. Am. Coll. Cardiol., January 1, 1999; 33(1): 46 - 52. [Abstract] [Full Text] [PDF]

				P. C. Deedwania Sotalol Is More Powerful Than Propranolol in Suppressing Complex Ventricular Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 259 - 272. [Abstract] [PDF]

				M. Nemeth, A. Varro, L. Virag, O. Hala, D. Thormahlen, and J. Gyula Papp Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 273 - 284. [Abstract] [PDF]

				D. Bocker, W. Haverkamp, M. Block, M. Borggrefe, D. Hammel, and G. Breithardt Comparison of d,l-Sotalol and Implantable Defibrillators for Treatment of Sustained Ventricular Tachycardia or Fibrillation in Patients With Coronary Artery Disease Circulation, July 15, 1996; 94(2): 151 - 157. [Abstract] [Full Text]

				K. Nademanee, H. E. Noll, and G. K. Feld Effects of Sotalol on His-Purkinje Conduction and Refractoriness in Humans Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 9 - 16. [Abstract] [PDF]

				C. Holubarsch, R. Schneider, B. Pieske, T. Ruf, G. Hasenfuss, G. Fraedrich, H. Posival, and H. Just Positive and Negative Inotropic Effects of DL-Sotalol and D-Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions Circulation, November 15, 1995; 92(10): 2904 - 2910. [Abstract] [Full Text]

				S. H. Hohnloser and R. L. Woosley Sotalol N. Engl. J. Med., July 7, 1994; 331(1): 31 - 38. [Full Text]

				R. Brooks, B. A. McGovern, H. Garan, and J. N. Ruskin Current Treatment of Patients Surviving Out-of-Hospital Cardiac Arrest JAMA, February 13, 1991; 265(6): 762 - 768. [Abstract] [PDF]